Madrigal Pharmaceuticals, Inc.
MDGL
Rang în acțiuni
#2013
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical... Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Preț acțiune
$446.50
Ultima sincronizare: 2026-10-19
Capitalizare de piață
$10.32B
Schimbare (1 zi)
-0.72%
Schimbare (1 an)
1.48%
Țară
US
Tranzacționează Madrigal Pharmaceuticals, Inc. (MDGL)
Categorie
Healthcare
Raport P/B pentru Madrigal Pharmaceuticals, Inc. (MDGL)
Raport P/B la data de October 2026 TTM: 25.60
Conform celor mai recente rapoarte financiare și prețului acțiunilor Madrigal Pharmaceuticals, Inc., raportul P/B actual (TTM) este 25.60. La sfârșitul anului 2023, compania avea un P/B de 10.67.
Istoricul raportului P/B pentru Madrigal Pharmaceuticals, Inc. din 2001 până în 2026
Raport P/B la sfârșitul fiecărui an
| An | Raport P/B | Schimbă |
|---|---|---|
| 2026 (TTM) | 25.60 | 194.25% |
| 2024 | 8.70 | -18.43% |
| 2023 | 10.67 | -57.67% |
| 2022 | 25.20 | 252.68% |
| 2021 | 7.15 | -0.16% |
| 2020 | 7.16 | 112.52% |
| 2019 | 3.37 | -3.71% |
| 2018 | 3.50 | -43.30% |
| 2017 | 6.17 | 189.53% |
| 2016 | 2.13 | 5,020.19% |
| 2015 | 0.04 | -98.96% |
| 2014 | 4.01 | -47.11% |
| 2013 | 7.58 | 6.16% |
| 2012 | 7.14 | -52.14% |
| 2011 | 14.91 | 41.78% |
| 2010 | 10.52 | 52.82% |
| 2009 | 6.88 | -296.01% |
| 2008 | -3.51 | -140.19% |
| 2007 | 8.74 | -107.54% |
| 2006 | -115.85 | -3,105.47% |
| 2005 | 3.85 | 167.44% |
| 2004 | 1.44 | -44.21% |
| 2003 | 2.58 | 0.00% |
| 2002 | 0.00 | -100.00% |
| 2001 | 9.71 | 0.00% |
Raport P/B pentru companii similare sau competitoare
| Companie | Raport P/B | Diferență raport P/B | Țara |
|---|---|---|---|
| 6.251 | -75.58% |
US
|
|
| 13.2547 | -48.22% |
US
|
|
| 4.208 | -83.56% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -75.85% |
NL
|
